News

Upon final approval, Teva's sumatriptan succinate tablets will be the AB-rated generic equivalent of GlaxoSmithKline's Imitrex tablets. Final approval is expected upon expiry of patent protection for the

The planned cut-back will see 2,200 employees in Pfizer’s sales organization lose their jobs in an effort to compensate for market changes and sales losses due to expiration

The company’s hospital-based products division, Abraxis Pharmaceutical Products, expects to commence marketing ampicillin and sulbactam immediately. The approval is the tenth product approval the company has received this

The primary endpoint is seroprotection four weeks after the third immunization. Data for the entire study population show that after two doses, Heplisav provided 98.5% seroprotection versus Engerix-B’s

Pfizer said the decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its

ISA247, which is referred to as LX211 by Lux, will be investigated in the oral capsule formulation for the treatment of active and control of uveitis, an autoimmune

Lilly will pay Applied NeuroSolutions $2 million, including a $500,000 equity investment in the company and will receive annual research and development support as part of the deal.

Aplindore was initially developed by Wyeth for schizophrenia and has been studied in six phase I and phase II clinical trials. The drug demonstrated excellent brain receptor occupancy

Barr plans to market pravastatin tablets in 10mg, 20mg, and 40mg strengths and has received tentative approval for 80mg strength and plans to launch this strength following the